Phaseline

Companies › Xuanzhu Biopharmaceutical

Xuanzhu Biopharmaceutical: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 3 Phase 3, 2 Phase 1; Oncology, Gastroenterology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XZP-3287–Phase 3Advanced Breast CancerNov 2029
Anaprazole
Proton pump inhibitor (PPI)
–Phase 3Reflux Esophagitis (RE)–
XZB-0004
AXL receptor tyrosine kinase inhibitor
AXLPhase 1Advanced Solid TumorFeb 2027
XZP-5955 tablets
NTRK and ROS1 fusion inhibitor
NTRK1, NTRK2, NTRK3, ROS1Phase 1Locally Advanced or Metastatic Solid TumorsJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07010107AnaprazolePhase 3Reflux Esophagitis (RE)GastroenterologyApr 2026
NCT05772455XZB-0004Phase 1Advanced Solid TumorOncologyFeb 2027
NCT04996121XZP-5955 tabletsPhase 1Locally Advanced or Metastatic Solid TumorsOncologyJun 2027
NCT05077449XZP-3287Phase 3Advanced Breast CancerOncologyNov 2029
NCT05257395XZP-3287Phase 3Advanced Breast CancerOncologySep 2030

Targets

NTRK1 (1) NTRK2 (1) NTRK3 (1) ROS1 (1) AXL (1)

Companies with the same targets

Nuvation Bio Roche Turning Point Therapeutics Bristol-Myers Squibb Dompé Farmaceutici Teligene US Bayer VM Oncology BnH Research Shaanxi Micot Pharmaceutical Technology

Companies built like this

Nuvation Bio Avistone Biotechnology Nuvalent Stemline Therapeutics InxMed (Shanghai)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.